Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?

Company Performance - Acrivon Therapeutics, Inc. (ACRV) has gained approximately 32.5% year-to-date, outperforming the average gain of 5.3% in the Medical sector [2] - Acrivon Therapeutics, Inc. holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [1] - The Zacks Consensus Estimate for ACRV's full-year earnings has increased by 17% over the past three months, reflecting improved analyst sentiment [2] Industry Comparison - Acrivon Therapeutics, Inc. is part of the Medical - Drugs industry, which has seen a decline of about 9.7% year-to-date, indicating that ACRV is performing better than its industry peers [3] - In contrast, the Medical Info Systems industry, which includes Hims & Hers Health, Inc. (HIMS), has experienced a decline of 17.9% since the beginning of the year [3] - Hims & Hers Health, Inc. has achieved a remarkable return of 151.6% year-to-date and has a Zacks Rank of 1 (Strong Buy) [2]